{"id":453632,"date":"2021-03-09T08:08:11","date_gmt":"2021-03-09T13:08:11","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=453632"},"modified":"2021-03-09T08:08:11","modified_gmt":"2021-03-09T13:08:11","slug":"corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/","title":{"rendered":"Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>Norwood, MA, March  09, 2021  (GLOBE NEWSWIRE) &#8212; <\/strong>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be presenting at two upcoming virtual investor conferences.<\/p>\n<p align=\"justify\">\u00a0The following are the details for the conferences:<\/p>\n<p>\n        <strong>33<sup>rd<\/sup> Annual Virtual Roth Conference <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0in;margin-bottom:0.0001pt\">Event: Fireside Chat Discussion and Q&amp;A<\/li>\n<li style=\"margin-top:0in;margin-bottom:0.0001pt\">Date and Time: Tuesday, March 16, 2021 at 1:30 PM EST<\/li>\n<\/ul>\n<p>\n        <strong>Oppenheimer 31<sup>st<\/sup> Annual Healthcare Conference<\/strong><br \/>\n        \n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0in;margin-bottom:0.0001pt\">Event: Fireside Chat Discussion and Q&amp;A<\/li>\n<li style=\"margin-top:0in;margin-bottom:0.0001pt\">Date and Time: Wednesday, March 17, 2021 at 1:10 PM EST<\/li>\n<\/ul>\n<p align=\"justify\">An audio webcast of the presentations will be accessible on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1k0kf8Ne2kHF42BMqTvLVe2GVnGSR_tBCI0Vm4jFYNgyam3KxQZbGZq0dxvoHzMB35RuA8awyDDQVLmF8RZIZw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Events<\/u><\/a> page of the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=StR28WNgl0qLqLipB1pfveLG-41ag-8JI6vR836DoMovnMfz95vMbdf9Sv8Zy_lMzXt3g80Jdpe3ng1qIFEy-w==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Investors<\/u><\/a> section of the Corbus website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JybxkJsjqk7mtysRpxMqzNOw_22rMpci51fbQdiefjELAQwzRSic6KksSpBnWGs8LFUnXlhkY1g8Ckkyhy-IMOSbrqk50zcefn7czdVU6Cg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.corbuspharma.com<\/u><\/a>. Replays will be available approximately one hour after each event and will be archived for 90 days following the event.<\/p>\n<p>\n        <strong>About Corbus<\/strong>\u00a0<\/p>\n<p align=\"justify\">Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company\u2019s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.<\/p>\n<p align=\"justify\">Lenabasum is not approved for the treatment of any indication. For more information on Corbus\u2019 clinical programs, please visit <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZNQTDlyS6GoGSDUtRhk1r-TRR69RqodmLt9lBCP_1dQjr65C6tgXVTt1CXfKJ7lkGawS_oC7VXZPDeC-tAViyq84di3rprmKwbJqjKCFKns=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a><\/u>.<\/p>\n<p align=\"justify\">For more information, visit <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wTP07O79LvnJGAo2UjwpMMrbjopx27GFRKuJCRb0mA8qRnPJb_kXPnaS3H3OALGNPpemWxKZe3q298vrMJ1kwCzbLqGgV9r-DY-vf3n1iN8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">http:\/\/www.corbuspharma.com\/<\/a><\/u>, and connect with us on <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ILF9vi3ufbKmMsY7aZN2ffODxPy8i3K5Cb0C3W1PmSlrJ9BU-cR-pW2wIt1EJtGnwvfICxe2aI_dzGZ7xRIOtg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Twitter<\/a><\/u>, <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UoU-p_0GhCgNCKsWXubo5MsIsG9U7AAUEfDqN5Ajb2GNKMG7z-iwbiPajIaPFLl_a24DcA6Pk4c4rfYCxZlE75JFb_ks6H8e6xY0eLlx5vZ9fTcqoScTT1SY8g1vHILx\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a><\/u>, and <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RU0Gc1j7tYlAwlGBNBVyBky_7W9BWY9AGhfW-rfCgAoR-GhBGQ0SeBSwu71Tsh4fD6CGbZz9wynNgUL43wVkPefRiFHmOdT6VR7vdhW3yHM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Facebook<\/a><\/u>.<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company&#8217;s restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management&#8217;s current beliefs and assumptions.<\/p>\n<p align=\"justify\">These statements may be identified by the use of forward-looking expressions, including, but not limited to, &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;potential,\u201d &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;would&#8221; and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company&#8217;s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>Corbus Pharmaceuticals Contacts: <\/strong>\n      <\/p>\n<p>Ted Jenkins, Senior Director, Investor Relations and Corporate Communications <br \/>Phone: +1 (617) 415-7745 <br \/>Email: <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jXINuZ59AfwciNdaBeFJPcRGDeDZruXOecUgW-2YNSzHOOtOlSss230Bbz9bb5_3LNhmiUwdMW_8GUulISqkFx0oFAT_naSWmEPbrN_fmQU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir@corbuspharma.com<\/a><\/u><\/p>\n<p>Lindsey Smith, Director, Investor Relations and Corporate Communications <br \/>Phone: +1 (617) 415-7749 <br \/>Email: <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=i5kZv1ipvy6W1Pw2n3zd2FFheP4myIjnuOqaQqEHn1nLQWmpzInk5NXr_0A7UPhZvvLtkIjWBn5UV3YridrrotUEeIkvtacu_q6buHJDwQA80QUdDYFOImOZv1esOlTN\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mediainfo@corbuspharma.com<\/a><\/u><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTQ2NCM0MDUxMjI3IzUwMDA0ODIwOQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/7777634b-f82d-475d-8609-e6df84368f93\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Norwood, MA, March 09, 2021 (GLOBE NEWSWIRE) &#8212; Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be presenting at two upcoming virtual investor conferences. \u00a0The following are the details for the conferences: 33rd Annual Virtual Roth Conference Event: Fireside Chat Discussion and Q&amp;A Date and Time: Tuesday, March 16, 2021 at 1:30 PM EST Oppenheimer 31st Annual Healthcare Conference Event: Fireside Chat Discussion and Q&amp;A Date and Time: Wednesday, March 17, 2021 at 1:10 PM EST An audio webcast of the presentations will be accessible on the Events page of the Investors section &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-453632","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Norwood, MA, March 09, 2021 (GLOBE NEWSWIRE) &#8212; Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be presenting at two upcoming virtual investor conferences. \u00a0The following are the details for the conferences: 33rd Annual Virtual Roth Conference Event: Fireside Chat Discussion and Q&amp;A Date and Time: Tuesday, March 16, 2021 at 1:30 PM EST Oppenheimer 31st Annual Healthcare Conference Event: Fireside Chat Discussion and Q&amp;A Date and Time: Wednesday, March 17, 2021 at 1:10 PM EST An audio webcast of the presentations will be accessible on the Events page of the Investors section &hellip; Continue reading &quot;Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-09T13:08:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTQ2NCM0MDUxMjI3IzUwMDA0ODIwOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences\",\"datePublished\":\"2021-03-09T13:08:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\\\/\"},\"wordCount\":580,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NTQ2NCM0MDUxMjI3IzUwMDA0ODIwOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\\\/\",\"name\":\"Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NTQ2NCM0MDUxMjI3IzUwMDA0ODIwOQ==\",\"datePublished\":\"2021-03-09T13:08:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NTQ2NCM0MDUxMjI3IzUwMDA0ODIwOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NTQ2NCM0MDUxMjI3IzUwMDA0ODIwOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences - Market Newsdesk","og_description":"Norwood, MA, March 09, 2021 (GLOBE NEWSWIRE) &#8212; Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be presenting at two upcoming virtual investor conferences. \u00a0The following are the details for the conferences: 33rd Annual Virtual Roth Conference Event: Fireside Chat Discussion and Q&amp;A Date and Time: Tuesday, March 16, 2021 at 1:30 PM EST Oppenheimer 31st Annual Healthcare Conference Event: Fireside Chat Discussion and Q&amp;A Date and Time: Wednesday, March 17, 2021 at 1:10 PM EST An audio webcast of the presentations will be accessible on the Events page of the Investors section &hellip; Continue reading \"Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-09T13:08:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTQ2NCM0MDUxMjI3IzUwMDA0ODIwOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences","datePublished":"2021-03-09T13:08:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/"},"wordCount":580,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTQ2NCM0MDUxMjI3IzUwMDA0ODIwOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/","name":"Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTQ2NCM0MDUxMjI3IzUwMDA0ODIwOQ==","datePublished":"2021-03-09T13:08:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTQ2NCM0MDUxMjI3IzUwMDA0ODIwOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTQ2NCM0MDUxMjI3IzUwMDA0ODIwOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corbus-pharmaceuticals-to-present-at-two-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453632","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=453632"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453632\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=453632"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=453632"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=453632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}